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BACKGROUND Elevated left atrial (LA) ﬁlling pressures leading to
pulmonary congestion is the common ﬁnal pathway in decom-
pensated heart failure (HF). The V-wave unidirectional shunt is a
novel percutaneously-implanted device intended to regulate LA
pressures by creating a low volume, left-to-right atrial shunt. The
objectives of this study were to evaluate the feasibility and pre-
liminary efﬁcacy of the V-Wave shunt for treating systolic HF.
METHODS Patients were enrolled if they had chronic cardiomyopathy
regardless of etiology with NYHA class III/IV symptoms, LVEF >15%
and 40% and PCWP 15 mmHg. All implants were performed
following femoral transseptal catheterization, under general anes-
thesia and TEE guidance. Patients were followed clinically and with
serial echo and RHC.
RESULTS Ten patients (90% male; 628 years, mean LVEF 277%)
underwent successful shunt implantation without complications
(average procedure time 5925 minutes without contrast injection).
One patient with prior history of severe ventricular arrhythmias died
after 2 months due to ’ventricular tachycardia storm.’ At 1-month, all
shunts were patent on TEE without evidence of thrombus or device
migration. Functional and hemodynamic results at 3 month follow-up
(ﬁrst 8 patients) are shown in the Table.N[8Group 1
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results and 1-year follow-up will be presented at the meeting.
Extensive evaluation of this novel therapeutic approach in patients
with symptomatic heart failure is warranted.
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BACKGROUND Paravalvular leak (PVL) after surgical valve replace-
ment is associated with heart failure and hemolytic anemia. Trans-
catheter PVL closure (TPVLC) is effective in reduction of HF
symptoms, however there are no prospective studies on effects on
hemolysis.
METHODS Prospective registry enrolled 75 adult patients after surgi-
cal valve prosthesis implantation with single PVL in aortic (n¼32) or
mitral (n¼43) location treated with TPVLC using AVPII, AVP III and
PLD devices. Criteria for closure were: signiﬁcant hemolytic anemia
and HF symptoms despite OMT and related to presence of PVL. He-
molysis was present in 46 (61,3%) pts with baseline HGB <11g% in
25(33,3%) and transfusions in 8 (10,7%) pts. HF symptoms and labo-
ratory data (hemoglobin, RBC, LDH) were assessed before, in-hospital
(3-5 d post procedure) and after 1 and 6 months. Regurgitant area in
color Doppler TEE was recorded using same settings in each obser-
vation and residual ﬂow location was assessed (through and/or beside
of occluder). Effects of TPVLC were quantitated depending on
reduction of regurgitation area respectively as class 1:< 50%, 2: 50-
75%, 3: 75-90%, 4: 90-99% and 5: complete closure.
RESULTS Comparison of patients with classes 1-3 (group 1) and clas-
ses 4-5 (group 2) with regard to baseline and follow-up hemolysis is
shown in table. TPVLC led to a signiﬁcant decrease of LDH activity
(LDH baseline vs LDH 6 months: 708.2 500.9 vs 433.0  189.0 IU/l)
and the follow-up values were signiﬁcantly lower in patients with
complete closure (class 5) of the defect versus incomplete (classes 1-4)
(367.08 83.59 vs. 474.65 185.02 IU/l, p¼0.03). Regurgitant area and
residual ﬂow through occluder were independent variables predictive
of the decrease in LDH (OR 9.69; 95%CI 1.85-109.88 and OR 5.36, 95%
CI 1.24-30.01, respectively)
CONCLUSIONS Only in patients with >90% reduction of regurgitation
area and no ﬂow through occluder TPVLC leads to recovery of Hb and
RBC levels and resolution of hemolysis in 6 months follow-up.
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